...
首页> 外文期刊>Ophthalmology >Novel glaucoma procedures: a report by the American Academy of Ophthalmology.
【24h】

Novel glaucoma procedures: a report by the American Academy of Ophthalmology.

机译:新型青光眼手术:美国眼科学院的报告。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To review the published literature and summarize clinically relevant information about novel, or emerging, surgical techniques for the treatment of open-angle glaucoma and to describe the devices and procedures in proper context of the appropriate patient population, theoretic effects, advantages, and disadvantages. DESIGN: Devices and procedures that have US Food and Drug Administration clearance or are currently in phase III clinical trials in the United States are included: the Fugo blade (Medisurg Ltd., Norristown, PA), Ex-PRESS mini glaucoma shunt (Alcon, Inc., Hunenberg, Switzerland), SOLX Gold Shunt (SOLX Ltd., Boston, MA), excimer laser trabeculotomy (AIDA, Glautec AG, Nurnberg, Germany), canaloplasty (iScience Interventional Corp., Menlo Park, CA), trabeculotomy by internal approach (Trabectome, NeoMedix, Inc., Tustin, CA), and trabecular micro-bypass stent (iStent, Glaukos Corporation, Laguna Hills, CA). METHODS: Literature searches of the PubMed and the Cochrane Library databases were conducted up to October 2009 with no date or language restrictions. MAIN OUTCOME MEASURES: These searches retrieved 192 citations, of which 23 were deemed topically relevant and rated for quality of evidence by the panel methodologist. All studies but one, which was rated as level II evidence, were rated as level III evidence. RESULTS: All of the devices studied showed a statistically significant reduction in intraocular pressure and, in some cases, glaucoma medication use. The success and failure definitions varied among studies, as did the calculated rates. Various types and rates of complications were reported depending on the surgical technique. On the basis of the review of the literature and mechanism of action, the authors also summarized theoretic advantages and disadvantages of each surgery. CONCLUSIONS: The novel glaucoma surgeries studied all show some promise as alternative treatments to lower intraocular pressure in the treatment of open-angle glaucoma. It is not possible to conclude whether these novel procedures are superior, equal to, or inferior to surgery such as trabeculectomy or to one another. The studies provide the basis for future comparative or randomized trials of existing glaucoma surgical techniques and other novel procedures.
机译:目的:回顾已发表的文献并总结有关开角型青光眼的新颖或新兴手术技术的临床相关信息,并在适当的患者群体,理论效果,优势和优势的适当背景下描述器械和程序缺点。设计:包括获得美国食品药品监督管理局许可或目前正在美国进行III期临床试验的设备和程序:Fugo刀片(Medisurg Ltd.,诺里斯敦,宾夕法尼亚州),Ex-PRESS迷你青光眼分流器(Alcon, Inc.(瑞士Hunenberg),SOLX Gold分流器(SOLX Ltd.,马萨诸塞州波士顿),准分子激光小梁切开术(AIDA,Glautec AG,纽伦堡,德国),管成形术(iScience Interventional Corp.,门洛帕克,加利福尼亚州),小梁切开术内部方法(Trabectome,NeoMedix,Inc.,Tustin,CA)和小梁微旁路支架(iStent,Glaukos Corporation,Laguna Hills,CA)。方法:对PubMed和Cochrane图书馆数据库进行的文献检索截止至2009年10月,没有日期或语言限制。主要观察指标:这些检索检索到192条引用文献,其中23条被认为是局部相关的,并且由方法论专家对证据的质量进行了评级。除一项被评定为II级证据外,所有研究均被评定为III级证据。结果:所有研究的设备均显示出眼内压的统计显着降低,在某些情况下,青光眼药物的使用也有所降低。在研究中,成功​​和失败的定义各不相同,计算的比率也不同。据报道,各种类型和并发症的发生率取决于手术技术。在回顾文献和作用机理的基础上,作者还总结了每种手术的理论优点和缺点。结论:所有研究的新型青光眼手术均显示出一定的前景,可作为降低开眼型青光眼的降低眼内压的替代疗法。无法断定这些新颖的手术方法是否优于,等同于或劣于小梁切除术等手术。这些研究为将来对现有青光眼手术技术和其他新方法的比较或随机试验提供了基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号